2011
Expression of αV-Integrins in Uterine Serous Papillary Carcinomas; Implications for Targeted Therapy With Intetumumab (CNTO 95), a Fully Human Antagonist Anti-αV-Integrin Antibody
Bellone M, Cocco E, Varughese J, Bellone S, Todeschini P, El-Sahwi K, Carrara L, Guzzo F, Schwartz PE, Rutherford TJ, Pecorelli S, Marshall DJ, Santin AD. Expression of αV-Integrins in Uterine Serous Papillary Carcinomas; Implications for Targeted Therapy With Intetumumab (CNTO 95), a Fully Human Antagonist Anti-αV-Integrin Antibody. International Journal Of Gynecological Cancer 2011, 21: 1084. PMID: 21633302, PMCID: PMC3690508, DOI: 10.1097/igc.0b013e3182187324.Peer-Reviewed Original Research
2010
Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro
Cross SN, Cocco E, Bellone S, Anagnostou VK, Brower SL, Richter CE, Siegel ER, Schwartz PE, Rutherford TJ, Santin AD. Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro. American Journal Of Obstetrics And Gynecology 2010, 203: 162.e1-162.e8. PMID: 20417484, PMCID: PMC2918912, DOI: 10.1016/j.ajog.2010.02.056.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsApoptosisCarboplatinCell Line, TumorCell ProliferationCisplatinCystadenocarcinoma, PapillaryCystadenocarcinoma, SerousDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedProbabilityReceptor, ErbB-2Sensitivity and SpecificityUterine NeoplasmsConceptsSingle-agent chemotherapyLow HER-2/neu expressionCell linesHER-2/neu expressionEffective chemotherapy regimensPlatinum-based chemotherapySerous papillary adenocarcinomaHalf-maximum inhibitory concentrationPlatinum compoundsLow half-maximum inhibitory concentrationChemotherapy regimensAdverse prognosisPapillary adenocarcinomaCarcinoma cell linesNeu expressionNeu overexpressionChemotherapy agentsPapillary carcinoma cell line
2007
Overexpression of claudin‐3 and claudin‐4 receptors in uterine serous papillary carcinoma
Santin AD, Bellone S, Marizzoni M, Palmieri M, Siegel ER, McKenney JK, Hennings L, Comper F, Bandiera E, Pecorelli S. Overexpression of claudin‐3 and claudin‐4 receptors in uterine serous papillary carcinoma. Cancer 2007, 109: 1312-1322. PMID: 17326053, DOI: 10.1002/cncr.22536.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnimalsClaudin-3Claudin-4Clostridium perfringensCystadenocarcinoma, PapillaryCystadenocarcinoma, SerousDrug Resistance, NeoplasmEnterotoxinsFemaleGene ExpressionHumansInjections, IntraperitonealMembrane ProteinsMiceMice, SCIDMiddle AgedReverse Transcriptase Polymerase Chain ReactionRNA, MessengerTumor Cells, CulturedUp-RegulationUterine Cervical NeoplasmsXenograft Model Antitumor AssaysConceptsUterine serous papillary carcinomaClaudin-4 receptorsUSPC cell linesSerous papillary carcinomaClaudin-3Endometrial cancerPapillary carcinomaClaudin-4 protein expressionChemotherapy-resistant variantsCytotoxic Clostridium perfringensSublethal intraperitoneal injectionsReverse transcriptase-polymerase chain reactionQuantitative reverse transcriptase-polymerase chain reactionTumor cell necrosisSCID mouse xenograftsType-specific therapiesDose-dependent cytotoxic effectCell linesTight junction proteinsControl tissue samplesHigh-affinity receptorAggressive variantTumor disappearanceIntraperitoneal injectionPolymerase chain reaction
2006
Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas
Santin AD, Diamandis EP, Bellone S, Marizzoni M, Bandiera E, Palmieri M, Papasakelariou C, Katsaros D, Burnett A, Pecorelli S. Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas. American Journal Of Obstetrics And Gynecology 2006, 194: 1296-1302. PMID: 16647913, DOI: 10.1016/j.ajog.2005.10.794.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCase-Control StudiesCell Line, TumorCystadenocarcinoma, PapillaryEnzyme-Linked Immunosorbent AssayFemaleHumansIn Vitro TechniquesKallikreinsMiddle AgedUterine NeoplasmsConceptsUterine serous papillary carcinomaSerous papillary carcinomaPapillary carcinoma patientsCarcinoma patientsEndometrioid carcinomaPapillary carcinomaKallikrein 10Benign diseaseSecretion levelsEndometrioid carcinoma patientsNormal healthy femalesTumor culturesSerous papillary tumorsCell biopsyPrimary endometrioid carcinomaNon-cancer groupExpression levelsReal-time polymerase chain reactionGene expression levelsPrimary tumor culturesAggressive variantHealthy womenCarcinoma cell linesPapillary tumorsEndometrial tumors
2005
Amplification of c‐erbB2 oncogene
Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S. Amplification of c‐erbB2 oncogene. Cancer 2005, 104: 1391-1397. PMID: 16116605, DOI: 10.1002/cncr.21308.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedBiomarkers, TumorBiopsy, NeedleCystadenocarcinoma, PapillaryFemaleGene AmplificationGene Expression Regulation, NeoplasticGenes, erbB-2HumansImmunohistochemistryIn Situ Hybridization, FluorescenceMiddle AgedProbabilityPrognosisReceptor, ErbB-2Risk AssessmentSampling StudiesSensitivity and SpecificityStatistics, NonparametricSurvival AnalysisUterine NeoplasmsConceptsNeu gene amplificationHER-2/neu geneEndometrial carcinomaGene amplificationSerous papillary endometrial carcinomaTumor cellsHER-2/neuNeu genePapillary endometrial carcinomaKaplan-Meier curvesImportant prognostic indicatorAfrican American patientsDisease-related deathLog-rank testShorter survival timeFISH-negative patientsNovel treatment strategiesC patientsSame tumor samplesAggressive variantPatient survivalPoor outcomePoor prognosisPrognostic indicatorClinical managementHigh serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer
Bellone S, Watts K, Cane' S, Palmieri M, Cannon MJ, Burnett A, Roman JJ, Pecorelli S, Santin AD. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecologic Oncology 2005, 98: 92-98. PMID: 15904949, DOI: 10.1016/j.ygyno.2005.03.016.Peer-Reviewed Original ResearchMeSH KeywordsAdultCystadenocarcinoma, PapillaryDrug Resistance, NeoplasmEndometrial NeoplasmsFemaleHumansInterleukin-6Middle AgedNeoplasm StagingPolymerase Chain ReactionConceptsUterine serous papillary carcinomaIL-6 gene expression levelsEndometrioid carcinomaInterleukin-6Primary endometrioid carcinomaEnzyme-linked immunosorbent assayEndometrial carcinomaHealthy femalesUSPC patientsMean serum IL-6 levelPrimary USPC cell linesIL-6 serum concentrationsSerum IL-6 levelsAnti-tumor immune functionBenign abdominal diseasesChemotherapy-resistant variantsControl endometrial cellsNormal healthy femalesSerous papillary histologyUSPC cell linesIL-6 concentrationsIL-6 levelsBenign disease patientsHigher serum levelsSerous papillary carcinomaDetermination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization
Santin AD, Bellone S, Van Stedum S, Bushen W, De Las Casas LE, Korourian S, Tian E, Roman JJ, Burnett A, Pecorelli S. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecologic Oncology 2005, 98: 24-30. PMID: 15894362, DOI: 10.1016/j.ygyno.2005.03.041.Peer-Reviewed Original ResearchHuman Kallikrein 6: A New Potential Serum Biomarker for Uterine Serous Papillary Cancer
Santin AD, Diamandis EP, Bellone S, Soosaipillai A, Cane S, Palmieri M, Burnett A, Roman JJ, Pecorelli S. Human Kallikrein 6: A New Potential Serum Biomarker for Uterine Serous Papillary Cancer. Clinical Cancer Research 2005, 11: 3320-3325. PMID: 15867230, DOI: 10.1158/1078-0432.ccr-04-2528.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorCarcinoma, EndometrioidCystadenocarcinoma, PapillaryCystadenocarcinoma, SerousEndometrial NeoplasmsEnzyme-Linked Immunosorbent AssayFemaleGene Expression Regulation, NeoplasticHumansKallikreinsMiddle AgedReverse Transcriptase Polymerase Chain ReactionRNA, MessengerTumor Cells, CulturedUterine NeoplasmsConceptsUterine serous papillary carcinomaSerous papillary carcinomaEndometrioid carcinomaUSPC patientsBenign diseasePapillary carcinomaNovel biomarkersPrimary USPC cell linesUterine serous papillary cancerOvarian serous papillary carcinomaEndometrioid carcinoma patientsNormal healthy femalesUSPC cell linesEarly disease recurrenceNormal endometrial cellsPotential serum biomarkersPrimary endometrioid carcinomaNew Potential Serum BiomarkerExpression levelsGene expression levelsHK6 proteinEndometrial biopsyCarcinoma patientsDisease recurrenceEndometrial cancerGene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy
Santin AD, Zhan F, Cane' S, Bellone S, Palmieri M, Thomas M, Burnett A, Roman JJ, Cannon MJ, Shaughnessy J, Pecorelli S. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. British Journal Of Cancer 2005, 92: 1561-1573. PMID: 15785748, PMCID: PMC2362016, DOI: 10.1038/sj.bjc.6602480.Peer-Reviewed Original ResearchConceptsUterine serous papillary cancerNormal endometrial cellsEndometrial cancerAggressive variantClaudin-4Normal endometrial epithelial cellsUterine serous papillary carcinomaAdhesion moleculesNovel therapeutic markerCommon gynecologic tumorsSerous papillary carcinomaParaffin-embedded specimensEndometrial epithelial cellsL1 cell adhesion moleculeType-specific therapiesRas homolog gene familyQuantitative RT-PCRScalar dosesGynecologic tumorsPapillary cancerEndometrial cellsInterleukin-6Cell adhesion moleculeNovel molecular markersPapillary carcinoma
2003
HER2/neu overexpression: has the Achilles’ heel of uterine serous papillary carcinoma been exposed?
Santin AD. HER2/neu overexpression: has the Achilles’ heel of uterine serous papillary carcinoma been exposed? Gynecologic Oncology 2003, 88: 263-265. PMID: 12648572, DOI: 10.1016/s0090-8258(02)00094-x.Peer-Reviewed Original Research
2002
Overexpression of HER-2/neu in uterine serous papillary cancer.
Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O'Brien T, Cannon MJ, Parham GP. Overexpression of HER-2/neu in uterine serous papillary cancer. Clinical Cancer Research 2002, 8: 1271-9. PMID: 12006548.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal, Murine-DerivedAntineoplastic AgentsBreast NeoplasmsCell DivisionCystadenocarcinoma, PapillaryCystadenocarcinoma, SerousFemaleFlow CytometryHumansImmunohistochemistryInterleukin-2Killer Cells, NaturalMiddle AgedNeoplasm StagingOvarian NeoplasmsReceptor, ErbB-2RituximabTrastuzumabTumor Cells, CulturedUterine NeoplasmsConceptsUterine serous papillary carcinomaAntibody-dependent cellular cytotoxicityUSPC cell linesIntensity of expressionOvarian cancerPrimary USPC cell linesUterine serous papillary cancerCell linesFlow cytometryHigh-grade ovarian cancerOvarian cancer cell linesSerous papillary carcinomaCell proliferationComplement-dependent cytotoxicityComplement-mediated cytotoxicityAttractive therapeutic strategyHuman serum IgGCancer cell linesEndometrial cancerNatural killerAggressive variantEffector cellsSerum IgGPapillary cancerIL-2
2000
Induction of Ovarian Tumor-Specific CD8+ Cytotoxic T Lymphocytes by Acid-Eluted Peptide-Pulsed Autologous Dendritic Cells
SANTIN A, BELLONE S, RAVAGGI A, PECORELLI S, CANNON M, PARHAM G. Induction of Ovarian Tumor-Specific CD8+ Cytotoxic T Lymphocytes by Acid-Eluted Peptide-Pulsed Autologous Dendritic Cells. Obstetrics And Gynecology 2000, 96: 422-430. DOI: 10.1097/00006250-200009000-00019.Peer-Reviewed Original ResearchConceptsAutologous tumor cellsAdvanced ovarian cancerT lymphocyte responsesCytotoxic T lymphocytesDendritic cellsT lymphocytesOvarian cancerTumor cellsLymphocyte responsesTumor-specific cytotoxic T-cell responseTumour peptide-pulsed dendritic cellsAutologous ovarian cancer cellsAutologous ovarian tumor cellsPeptide-pulsed dendritic cellsAnti-HLA class ICytotoxic T lymphocyte responsesCytotoxic T cell responsesTwo-color flow cytometric analysisPeripheral blood mononuclear cellsHLA-A2 monoclonal antibodyClass IAutologous dendritic cellsTumor-specific CD8T cell responsesStrong cytolytic activityInduction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells.
Santin A, Bellone S, Ravaggi A, Pecorelli S, Cannon M, Parham G. Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstetrics And Gynecology 2000, 96: 422-30. PMID: 10960637, DOI: 10.1016/s0029-7844(00)00916-9.Peer-Reviewed Original ResearchConceptsAutologous tumor cellsAdvanced ovarian cancerPeptide-pulsed dendritic cellsT lymphocyte responsesDendritic cellsT lymphocytesOvarian cancerTumor cellsLymphocyte responsesTumor-specific cytotoxic T-cell responsePeptide-pulsed autologous dendritic cellsTumour peptide-pulsed dendritic cellsAutologous ovarian cancer cellsAutologous ovarian tumor cellsAnti-HLA class ICytotoxic T lymphocyte responsesCytotoxic T cell responsesTwo-color flow cytometric analysisPeripheral blood mononuclear cellsHLA-A2 monoclonal antibodyClass IAutologous dendritic cellsTumor-specific CD8T cell responsesStrong cytolytic activity
1995
Development and Characterization of an IL-4-Secreting Human Ovarian Carcinoma Cell Line
Santin A, Ioli G, Hiserodt J, Rose G, Graf M, Tocco L, Lander J, Eck L, Burger R, DiSaia P, Pecorelli S, Granger G. Development and Characterization of an IL-4-Secreting Human Ovarian Carcinoma Cell Line. Gynecologic Oncology 1995, 58: 230-239. PMID: 7622110, DOI: 10.1006/gyno.1995.1216.Peer-Reviewed Original ResearchMeSH KeywordsAntigens, NeoplasmAntigens, SurfaceCell DivisionCell SurvivalClone CellsCystadenocarcinoma, PapillaryDNA, NeoplasmDNA, ViralFemaleGenetic VectorsHistocompatibility Antigens Class IHumansIntercellular Adhesion Molecule-1Interleukin-4KineticsOvarian NeoplasmsPlasmidsRetroviridaeTransduction, GeneticTumor Cells, CulturedVaccinesConceptsHuman ovarian carcinoma cell linesOvarian carcinoma cell linesCarcinoma cell linesInterleukin-4UCI-107Detectable MHC class IICell linesAdvanced ovarian cancerIL-4 secretionMHC class IICytokine interleukin-4IL-4 receptorMHC class ILXSN retroviral vectorOvarian carcinoma cellsIL-4 geneMonths of studyCA 125Ovarian cancerICAM-1Parental cell lineDay 8Vector control cellsClass IIUCI 101